Clinical Trials Directory

Trials / Completed

CompletedNCT00054041

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
84 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
Female
Age
17 Years
Healthy volunteers
Not accepted

Summary

Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer. Randomized phase II trial to study the effectiveness of vaccine therapy in preventing cervical cancer in patients who have cervical intraepithelial neoplasia

Detailed description

PRIMARY OBJECTIVES: I. Determine the efficacy of SGN-00101, in terms of complete histologic regression, in patients with grade III cervical intraepithelial neoplasia. II. Determine the toxicity of this drug in these patients. SECONDARY OBJECTIVES: I. Determine change in lesion size in these patients after treatment with this drug. II. Compare histologic response before and after treatment with this drug in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. Arm II: Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy. Patients are followed at 19 weeks, every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 28-84 patients (14-42 per treatment arm) will be accrued for this study within 12-48 months.

Conditions

Interventions

TypeNameDescription
BIOLOGICALHspE7Given subcutaneously
PROCEDUREtherapeutic conventional surgeryUndergo large loop excision
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2004-06-01
Primary completion
2007-01-01
First posted
2003-02-06
Last updated
2013-01-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00054041. Inclusion in this directory is not an endorsement.